Efficacy Analysis on Intravesical Instillation of Epirubicin and Gemcitabine in Patients with High-risk Non-muscle Invasive Bladder Cancer
HU Xiao-yan
CHEN Yi
YING Min
TU Hai-yan
WANG Kui
XIANG Hua-ying
Abstract：Objective To compare clinical efficacy of intravesical instillation of epirubicin (EPI) and gemcitabine (GEM) for high-risk non-muscle invasive bladder cancer (NMIBC).Methods A total of 165 high-risk NMIBC patients in authors, hospital from July 2013 to April 2016 were retrospectively analyzed.All patients were randomly divided into auxiliary bladder perfusion chemotherapy EPI group (n=76) and GEM group (n=89) after implemented with transurethral resection of bladder tumor (TURBT).The tumor recurrence rate, time of recurrence, progression-free survival and adverse effects were evaluated.Results All patients were followed up, 3 cases in EPI group had severe perfusion side effects and stopped treatments, the tumor recurrence rate (24.72% vs.42.47%) of group GEM was significantly lower than that in group EPI (X2=5.738, P=0.017).There were no significantly different in tumor progression rates (12.36% vs.21.92%, X2=2.638, P=0.104) ,perfusion complications (X2=2.792, P=0.095) between groups GEM and EPI.Conclusion This study suggests that intravesical chemotherapy with EPI and GEM treatment can reduce tumor recurrence,but do not reduce tumor progress.GEM for preventing tumor recurrence curative effect is superior to EPI.
Keywords：EpirubicinGemcitabinePerfusion chemotherapyHigh-risk non-muscle invasive bladder cancer
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 383-386,393 )